Phase 1 trial (181 participants) of inhaled anti-TSLP fragment AZD8630/AMG 104 in healthy adults and adults with moderate-to-severe asthma: safety profile was acceptable; in asthma, 8 mg reduced FeNO by 23% vs placebo at day 28 (secondary, P=.037).
RCTn = 181
Doffman et al. AZD8630/AMG 104, an inhaled anti-thymic stromal lymphopoietin antibody fragment, for moderate-to-severe asthma: Phase 1 randomized controlled trial